Rx Medicare

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that it has completed patient enrollment in the efficacy portion of its initial Phase 3 clinical trial evaluating MAP0004, the company’s novel, orally inhaled product candidate for the acute treatment of migraine.

Read More…

Related Posts

• Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial In Patients With Migraine Headaches
• MAP Pharmaceuticals Phase 3 Trial Of Levadex? Migraine Product Candidate Meets All Four Primary Endpoints
• MAP Pharmaceuticals Phase 3 Trial Of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
• Phase IIa Clinical Trial Results Relating To CK-1827452 In Patients With Ischemic Cardiomyopathy And Angina
• Amarillo Biosciences Announces Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit In Preventing Influenza-Like Illness In Seniors
• Third Party Reexamination Of Javelin Pharmaceuticals’ Phase III Trial Data For Ereska Yields Statistically Significant Primary Endpoint
• Trigemina Conducting Phase IIa Clinical Trial In Chronic Daily Headache
• China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug
• Winston Laboratories, Inc. Announces Positive Top-line Results Of Phase II Clinical Trial Of Civamide Patch
• Biostar Pharmaceuticals, Inc. Receives The Chinese Military Drug Administration Clearance To Begin Clinical Trial For Zushima Analgesic Aerosol Spray
• Javelin Pharmaceuticals Reports Ereska (Intranasal Ketamine) Phase III Trial Results In Postoperative Orthopedic Pain
• Jazz Pharmaceuticals To Present Data From First Phase III Study Of Sodium Oxybate In Patients With Fibromyalgia
• Cerimon Pharmaceuticals Initiates Phase III Clinical Studies To Evaluate Its Topical Diclofenac Sodium Patch For Mild-to-Moderate Pain
• Addex Starts A Phase IIb Trial Of ADX10059 For Migraine Prevention
• MAP Pharmaceuticals Provides Update On Progress Of Two Phase 3 Clinical Programs

Tags: clinical, completion, enrollment, map0004, migraine, patients, pharmaceuticals, phase, trial

This entry was posted on Tuesday, January 27th, 2009 at 5:01 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.